News and Trends 8 Mar 2023How to promote diversity in STEM Leaders from OMass Therapeutics, SiSaf and Brainomix explain how to promote diversity in science, technology, engineering and math (STEM). OMass… March 8, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Expert Advice 2 Mar 20235 steps to strategic partnerships for healthtech startups By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities… March 2, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023FDA approves GSK drug for recurrent or advanced mismatch repair-deficient endometrial cancer GSK plc says the US Food and Drug Administration (FDA) has given full approval for Jemperli (dostarlimab-gxly) for the treatment… February 10, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023Cell and Gene Therapy Catapult boost for life science campus The Cell and Gene Therapy Catapult (CGT Catapult), an independent U.K. innovation and technology organization specializing in the advancement of… February 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022Sanofi and GSK Covid-19 booster vaccine approved by European Commission Sanofi and GSK’s Covid booster vaccine has been approved in Europe. After the European Medicines Agency’s Committee for Medicinal Products… November 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022Mersana Therapeutics announces collaboration with GSK for the co-development of cancer treatment A global collaboration was announced today (August 9) between Mersana Therapeutics Inc and GSK plc that will give GSK the… August 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2022GSK positive on RSV vaccine for older adults GSK plc has announced positive headline results from its AReSVi 006 phase III trial. AReSVi 006 is a phase III… June 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2022Upstream Bio to target asthma as it launches with $200M financing Upstream Bio, a U.S. biotech company focused on inflammation, today exited stealth mode with $200M Series A financing. The company… June 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2022GSK to acquire clinical-stage biopharmaceutical company Affinivax GSK plc is set to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1B… June 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2021GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for… June 30, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2021GSK Acne Deal Heralds Growing Interest in Skin Microbiome This week, the Paris-based Eligo Bioscience became one of a growing number of biotechs to land a big pharma deal… January 15, 2021 - 4 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jul 2020Pharma Giant GSK and mRNA Biotech CureVac Ink €1B Deal GlaxoSmithKline (GSK) has struck a deal worth up to €1B with the German biotechnology company CureVac to co-develop messenger RNA… July 23, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2020ViiV Healthcare’s Monthly HIV Injection Gains First Approval in Canada A monthly two-drug injection developed by the GSK spinoff ViiV Healthcare has been approved for the treatment of HIV in… March 23, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Feb 2020Update: Janssen and Maze Jump on Board Finnish Genomics Project Update (25/02/2020): Janssen and the US company Maze Therapeutics are the latest pharma companies to sign up as partners in… February 25, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Feb 2020Immatics Partners GSK in Deal Worth €1B to Develop Cancer Therapies The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing… February 20, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2019ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV The UK company ViiV Healthcare will begin a phase IIa trial of an antibody licensed from the National Institutes of… November 22, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2019European Project Launches to Tailor Autoimmune Disease Treatments Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict… October 31, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 7 Aug 2019Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience In less than two years, Orchard Therapeutics has changed from a small, relatively unknown UK biotech specializing in gene therapy… August 7, 2019 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2019EU Approves Two-Drug Pill as First-Line Treatment for HIV The two-drug pill Dovato, developed by the UK company ViiV Healthcare, has been approved as a first-line treatment for HIV,… July 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2019Update: Two-Drug HIV Treatment Effective for up to Three Years Update (04/04/2019): ViiV Healthcare's two-drug HIV treatment, Juluca, has successfully suppressed the HIV virus for up to three years in… April 4, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email